or contraindications to TNFi. An IL-17i biologic is recommended over an IL-12/23i biologic. An IL-12/23i biologic may be used instead of a TNFi biologic in patients who prefer less frequent drug administration, and instead of an IL-17i biologic in patients with concomitant IBD or who prefer less frequent drug administration. Active PsA with concomitant active IBD (Table 5). All recommendations for patients with active PsA with concomitant active IBD are strong based on moderate-quality